Affinity Life Sciences to Produce Lyophilized Chem-Bio Assays for SRC Acumen
SRC Acumen announced the continued and exclusive production of lyophilized qPCR and toxin assays by Affinity Life Sciences.
Amherst, NH, January 16, 2015 --(PR.com)-- Affinity Life Sciences, Inc. and SRC Acumen, LLC are announcing the continued production of freeze-dried qPCR and toxin assays. As part of this agreement, Affinity Life Sciences will manufacture these products exclusively for SRC Acumen.
SRC Acumen’s assays are unique in their ability to provide near real-time, interferent resistant, one-step identification of pathogens and toxins. They are used to support government and commercial customers with food, water, and public health monitoring; homeland security; biosurveillance; and chemical and biological defense.
Specific assays being produced include the Acu-Bot™, Acu-Ricin™ and Acu-PAPA™ SEB toxin assays for the identification of biologically active Botulinum neurotoxin (BoNT) A, Ricin, and Staphylococcus enterotoxin B (SEB). The qPCR assays include specific chemistries for the identification of Bacillus anthracis, Francisella tularensis, Yersinia pestis, Coxiella burnetti, Brucella spp., PanOrthopox and VEE viruses.
Paul G. Tremont, president of SRC said, “We required a teammate with the expertise needed to produce these important assays to ensure the highest quality for our customers. This collaboration with Affinity Life Sciences provides us with the capabilities needed for lyophilization, also known as freeze-drying, biomarker assay and quality control development and production.”
“We are delighted to be able to work with SRC,” said Tod Gavron, president of Affinity Life Sciences. “SRC is expanding the limits of what’s possible in biodefense threat identification, advancing assay technologies that deliver fast, reliable and relevant information. Their assays are valuable tools for critical decision makers in the field.”
About SRC Acumen, LLC
SRC Acumen, LLC is a subsidiary of SRC, Inc., a not-for-profit research and development company with more than 55 years of experience in defense, environment and intelligence. SRC Acumen is focused on bringing chem-bio threat identification and detection capabilities to the commercial and civilian government marketspaces. For more information about SRC Acumen and their product catalog, please visit www.srcacumen.com. For more information about SRC, Inc, visit www.srcinc.com.
About Affinity Life Sciences:
Affinity Life Sciences, located in Amherst, NH is a cGMP and ISO 13485 compliant company dedicated to the specific needs of the biotechnology and pharmaceutical markets. Affinity’s new 16,250 sq ft facility can provide custom services including in vitro diagnostic kit development and production, lyophilization, cell culture production, and bioanalytical testing. Learn more about Affinity Life Sciences at www.AffinityLifeSciences.com or contact Sales at (603) 718-1945 ext.102 or info@afflif.com to learn more about Affinity’s custom services.
SRC Acumen’s assays are unique in their ability to provide near real-time, interferent resistant, one-step identification of pathogens and toxins. They are used to support government and commercial customers with food, water, and public health monitoring; homeland security; biosurveillance; and chemical and biological defense.
Specific assays being produced include the Acu-Bot™, Acu-Ricin™ and Acu-PAPA™ SEB toxin assays for the identification of biologically active Botulinum neurotoxin (BoNT) A, Ricin, and Staphylococcus enterotoxin B (SEB). The qPCR assays include specific chemistries for the identification of Bacillus anthracis, Francisella tularensis, Yersinia pestis, Coxiella burnetti, Brucella spp., PanOrthopox and VEE viruses.
Paul G. Tremont, president of SRC said, “We required a teammate with the expertise needed to produce these important assays to ensure the highest quality for our customers. This collaboration with Affinity Life Sciences provides us with the capabilities needed for lyophilization, also known as freeze-drying, biomarker assay and quality control development and production.”
“We are delighted to be able to work with SRC,” said Tod Gavron, president of Affinity Life Sciences. “SRC is expanding the limits of what’s possible in biodefense threat identification, advancing assay technologies that deliver fast, reliable and relevant information. Their assays are valuable tools for critical decision makers in the field.”
About SRC Acumen, LLC
SRC Acumen, LLC is a subsidiary of SRC, Inc., a not-for-profit research and development company with more than 55 years of experience in defense, environment and intelligence. SRC Acumen is focused on bringing chem-bio threat identification and detection capabilities to the commercial and civilian government marketspaces. For more information about SRC Acumen and their product catalog, please visit www.srcacumen.com. For more information about SRC, Inc, visit www.srcinc.com.
About Affinity Life Sciences:
Affinity Life Sciences, located in Amherst, NH is a cGMP and ISO 13485 compliant company dedicated to the specific needs of the biotechnology and pharmaceutical markets. Affinity’s new 16,250 sq ft facility can provide custom services including in vitro diagnostic kit development and production, lyophilization, cell culture production, and bioanalytical testing. Learn more about Affinity Life Sciences at www.AffinityLifeSciences.com or contact Sales at (603) 718-1945 ext.102 or info@afflif.com to learn more about Affinity’s custom services.
Contact
Affinity Life Sciences
Tod Gavron
(603) 718-1790
www.affinitylifesciences.com
Tod Gavron
(603) 718-1790
www.affinitylifesciences.com
Contact
Categories